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Summary
Tumor necrosis factor a (TNF-ca), a major mediator of inflammation, also possesses a wide
pleiotropism of actions, suggesting its involvement in physiological conditions. TNF-a mRNA
is present in mouse embryonic tissues and also in fetal thymus and spleen. Repeated injections
of a monospecific polyclonal rabbit anti-mouse TNF-a antibody in mice, starting either during
pregnancy or at birth, led to a severe but transient growth retardation, already present at birth,
reaching a 35% decrease in body weight at 3 wk, with complete recovery at 8 wk. The insulin
growth factor I (IGF-I) blood levels were decreased to about 50%; growth hormone release and
otherendocrine functions were unaltered. A marked atrophy of the thymus, spleen, and lymph
nodeswasalso observed, with lymphopeniaandimpaired developmentof T andBcell peripheral
lymphoid structures. The pathways involving TNF-a in IGF-I release and early body growth
are probably distinct from thoseby which TNF-a participates in early development of lymphoid
tissues, where its low physiological release may contribute to enhance lymphoid cell expansion.
T
NF-ca, a cytokine that is produced in the largest amounts
by activated macrophages but that can also be released
by awide variety of othercells, is one of the majormediators
of inflammation and is involved in a number of infectious
andparasitic diseases (1-4). It is also a very pleiotropic agent
acting on numerous tissues, and thus is suspected to partici-
pate in various physiological functions (2-4). TNF mRNA
hasbeen detected in mouse embryos (5), in human fetal thymus
(6), andin both extraembryonic and maternal tissues during
pregnancy (7). Biologically active TNF has been detected in
the amniotic fluid as well as in supernatant culture media
from human placentalanddecidual explants (8, 9). To inves-
tigate thepossibility that TNF is involved in some develop-
mental steps, this study used the approach of repeatedly in-
jecting pregnant mice or pups at birth with high amounts
of a monospecific neutralizing rabbit anti-murine TNF an-
tibody.
Materials and Methods
Antibodies.
￿
IgG fractions of either rabbit antiserum to mouse
TNF-cr or normal rabbit serumwere prepared by protein A-Sepha-
rose chromatography (Pharmacia Fine Chemicals, Uppsala, Sweden).
These fractions were ultracentrifuged at 150,000 g for 150 min,
and only the upperthird, deaggregated fractions were used to in-
duce and maintain toleranceto rabbit IgG. When affinity-purified
anti-TNF antibody wasused, it wasobtained by elution with 0.58%
acetic acid in 150 mM NaCl from acolumn containing 1 mg recom-
binant mouseTNF (gift of B. Allet, Glaxo I.M.B., Geneva, Swit-
zerland) coupled to Affigel 10 (Bio-Rad Laboratories, Richmond,
CA), after prior washing with 2 M NaCl, followed by dialysis
against PBS, pH 7.4. Four differentbatches ofantiTNF antibodies
(obtained from the sera of differentrabbits) were used in these ex-
periments.
In Vivo Treatments.
￿
Pregnant outbred NMRI mice were ob-
tained from IFFA-Credo (Lyon, France), housed in our facilities,
andkept under a laminar flow. Neomycin was added to drinking
water. Mice were injected intraperitoneally with either 1 mg of
antiTNF IgGor normal (n)IgG, or with 50 p.g ofaffinity-purified
antiTNF antibody or nIgG. Two injection schedules were used.
(a) Starting on days 11, 13, and 15 of pregnancy, the offspringwere
injected every other day with the same amounts of antibody or
nIgG. (b) Starting on day 2 after birth, neonates of the same litter
were injected with antibody or nIgG every 3 d.
Hormonal Assays.
￿
Mice were decapitated between 9 and 10 a.m.
in conditions ensuring theleastpossible stress. Insulingrowth factor
I (IGF-I)1 and growth hormone (GH) serum levels were measured
by specific RIAs usingkits provided by NIAMDD, National Pitu-
1 Abbreviations used in this paper. AP, anterior pituitary gland; GH, growth
hormone; GHRF, growth hormone-releasing factor; IGF-I, insulin growth
factor I.
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Volume 176 November 1992 1259-1264itary Agency. For IGF-IRIA (10), antibodywas generously provided
by Dr. L . Underwood (University of North Carolina, Chapel Hill,
NC), and standard by Kaby Pharmacia Peptide Hormones (Stock-
holm, Sweden) . For GH RIA, antibody and standard were sup-
plied by the National Institutes of Health (Bethesda, MD), except
for the first antiserum, which was kindly given by Dr. Y Sinha
et al . (11) . For the study of GH release in vitro, four anterior
pituitaries from antiTNF antibody-treated mice and four from nIgG
control mice were packed in 2-ml plastic syringes superfused (0.35
ml/min) with medium only (Earle's balanced salt solution + HSA)
or containing various concentrations of GH-releasing factor (GHRF)
as described (12) . 3-min fractions were collected and GH concen-
trations were determined by RIA . For the determination of cor-
ticosterone blood levels, blood samples were centrifuged at low
speed, and the plasmid was stored frozen (-20°C) until direct
RIA (13) .
Hematological Assays. Differential white blood cell (WBC)
counts were performed on Giemsa-stained blood smears . Colony-
forming cell assays in the presence of 11,3 and erythropoietin were
performed as described (14) .
Histology.
￿
Histological sections of tissues obtained at autopsy
were stained with hematoxylin and eosin . Photographs were taken
with a photomicroscope (Carl Zeiss, Inc ., Oberkochen, Germany) .
Northern Blot Analysis.
￿
Detection ofTNF-specificmRNA was
performed by Northern blot analysis using a radiolabeled pSP65-
TNF cRNA probe after glyoxylation of 6 Ag total RNA, separa-
tion by agarose gel electrophoresis, and transfer to Biodyne mem-
branes (Pall Ultrafine Filtration Corporation, Glen Cove, NY), fol-
lowed byprehybridization and hybridization conditions as described
(15) . Filters were exposed to Kodak XAR-5 films at -70°C with
intensifier screens (Du Pont Cronex, Boston, MA) .
Statistical Analysis.
￿
Significance analysis between results obtained
from various groups was performed by using the nonparametric
MannWhitney U-test . Probability values >5% were considered
significant .
Results and Discussion
Pregnant mice received rabbit antiTNF antibody, either
as a total IgG fraction or as affinity-purified antibody, or
normal rabbit IgG as control, on days 11, 13, and 15 of preg-
nancy. At birth, newborn mice ofantiTNF antibody-treated
mothers were consistently smaller (Fig. 1 A), with an av-
erage weight of 1.4 ± 0.3 g (mean ± SD ; n = 24) vs. 1.7
± 0.5 g (n = 23) (p <0.001) . In a typical experiment, four
of the pups in each group were killed for blood sampling
and histological examination, with 16 others receiving in-
traperitoneal injections of the same amount and type of IgG
as given to their mothers, every other day. Eight of these
mice were killed at 9 d, and eight at 21 d of age, at which
time the antiTNF antibody-treated mice weighed on average
34% less than their matched controls (Fig. 1, A and B, at
3 wk of age ; p <0.01) . A comparable difference in size, as
assessed by measurement of the rump-to-tail and tail lengths,
was revealed (a 25% decrease average in 3-wk-old antiTNF
antibody-treated mice) (n = 8 per group ; p < 0.01) . This
protocol was repeated four times with consistent results . To
investigate whether the observed effects on growth were per-
manent, after 3 wk of treatment with antiTNF antibody,
mice were divided into two groups : one (n = 8) continued
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to receive the antiTNF antibody as described for an addi-
tional 3 wk, and in the other group (n = 8), the injections
were discontinued . From day 21 to 43, no significant differ-
ence in body weight (Fig . 1, A and C) or size (not shown)
was observed between the two groups, previously treated with
antiTNF antibodies or still on treatment, although there was
still at 43 d a statistical difference (p = 0.03) with mice
receiving nIgG only. At 58 d, however, controls and mice
that had stopped receiving the antiTNF antibodies 2 wk earlier
no longer showed a significant difference in weight (Fig . 1A) .
To exclude an effect related to an interference with placental
development, a similar schedule ofinjections was started after
birth, on the second day of life. At 7 d, the difference in weight
ofantiTNF antibody-treated (3.1 ± 0.4 g ; n = 14) and con-
trol pups (4.4 ± 0.3 g ; n = 12) was highly significant
(p <0.001), and at 3 wk, it was comparable to that shown
in Fig. 1 A . Combining these two protocols of injections,
starting during pregnancy or after birth, a total of 103 anti-
TNF antibody-treated mice (44 with IgG fraction and 59
with purified antibody) were compared and killed at various
intervals between 2 and 58 d of age. The average weight in
3-wk-old antiTNF antibody-treated mice (11.4 ± 3.2 g ;
n = 42) was 37.5% less than in controls (18.3 ± 3.2 g ; p
<0.001) . Taken together, these results show that : (a) anti-
TNF antibody treatment affects somatic growth already in
utero, but is also effective when begun immediately after birth ;
and (b) the effect of the antibody treatment is reversible with
time . Except for the alteration of the lymphoid organs, de-
scribed below, gross and histological examination of liver,
lung, kidney, adrenals, heart, and pituitary were comparable
in both groups, with no detectable evidence ofacute or chronic
infection in the smaller mice .
To search for possible endocrine and metabolic alterations
associated with this growth retardation, the levels of IGF-I
were first explored in the pooled sera of three 2-d-old pups
from an antiTNF antibody-treated mother and of three
3-wk-old mice treated since birth . The IGF-I serum levels
were, respectively, 43% and 51% those of matched controls .
To extend these observations, IGF-I and GH levels were mea-
sured in the sera of 21-, 43-, and 58-d-old mice (Table 1) .
While no difference was observed in GH levels at any age,
the IGF-I levels were again markedly decreased in antiTNF
antibody-treated mice at 3wk . This difference, although less
pronounced, was still persistent at 43 and 58 d, when anti-
TNF antibody-treated mice had regained a weight and size
comparable to that of controls. All groups of mice presented
comparableGH contents of the anterior pituitary gland (AP),
and comparable GH release in vitro in response to GHRF
(not shown), except in 43-d-old mice, where theAP response
to 10 - ' M GHRF was significantly higher in antiTNF
antibody-treated mice (400 ± 9 pg/ml) than in controls (150
± 22 pg/ml ; p<0.05) . Since this was the time when treated
mice started recovering a normal weight, this raised the pos-
sibility of a role of GH in this catch-up phenomenon . Cor-
ticosterone levels oftreated mice were not significantly different
from those of controls at 9 (0.7 ± 0.1 vs . 0.4 ± 0.02 ug ;
n = 8), 21 (10.2 ± 1.8 vs. 6.2 ± 1.4 ug; n = 8), or 43L
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Table 1 .
￿
Effect of Anti-TNF Antibody Treatment on GH
￿
d (11.2 ± 2.6 vs . 6 .6 ± 2.6 lAg ; n = 4), as were ACTH
and IGF-1 Levels
￿
contents of the AP and ACTH release in vitro in response
to corticotropin-releasing hormone (not shown) . This ex-
plorationwasperformed sinceTNF-oz hasbeen shown, under
certain conditions, to modulate the corticotroph axis (16) .
Since, in vitro, TNF hasbeen shownto stimulate hexose trans-
port and to increase the level of glucose-transporter (Glut-1)
mRNA expression (17), an effect that might affect growth,
the levels of Glut-1 mRNA were analyzed in the striated
muscle of 1-wk-old pups of mothers having received anti-
TNFantibody (n = 6) or nIgG during pregnancy ; no differ-
ence was found (not shown) . Finally, no difference was ob-
served in blood glucose levels between antiTNF antibody-
treated and control mice .
Thus, the only endocrine disturbance detected in antiTNF
* Pool of eight mice .
￿
antibody-treated mice that appears to be related to their
1 Pool of four mice.
￿
retarded growth is the prolonged decrease in IGF-I serum
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Figure 1 .
￿
Effect of antiTNF antibody
treatment on growth . (A) Growth curve
of antiTNF antibody-treated and control
mice between birth and 58 d of age . Sig-
nificance analysis between results obtained
from various groups was performed by
using the nonparametric Mann-WhitneyU
test . Values <5% were considered sig-
nificant (* ). (B)A3-wk-old mouse treated
with antiTNF antibody was smaller than
its littermate treated with nIgG (9 .1 vs.
17 .2 g) . (C) At 3 wk of age, antiTNF
antibody-treated mice were divided in two
groups . One group continued to receive
antiTNF antibody following the same
schedule as described for an additional 3 wk
(antiTNF),and the second group received
nIgG instead (stop) . No difference in body
weight or size was observed between the
two groups. A significant difference was
noted between controls and mice previously
treated or still on treatment : (*)p <0.01 ;
(* *) p <0.05) . Persistance of antiTNF an-
tibody activity in serumwas found to range
between 72 and 1,200 neutralizing units/ml
4 d after the last injection .
Day Treatment GH IGF-I
ng/ml ng/ml
21 nIgG 3.9 ± 0 .3 465 .55*
Anti-TNF 4.8 ± 0.5 235 .90*
43 nIgG 3.1 ± 0 .05 463.47#
Anti-TNF 3.4 ± 0.13 322.181
58 nIgG 4.1 ± 0 .7 452.561
Anti-TNF 4.3 ± 0.5 359 .521levels. Results of the treatment when started at birth rule
out the possibility ofa deleterious effect on placental growth.
The decreased size at birth as well as the absence of gross
histologic signs ofinfection argue against an explanation based
on a higher vulnerability to infectious agents, which could
result from a lack of TNF and from the impaired develop-
ment of the lymphoid system described below. Most impor-
tantly, infection leads to elevated corticosterone levels, which
were not observed in antiTNF antibody-treated mice.
Hyponutrition, known to decrease IGF-I levels (18), would
not explain the intriguing discrepancy observed on the eighth
week between persisting low IGF-I levels and resumption of
normal body weight. Signs ofhepatic disease, which can cause
decreased IGF-Iproduction (19), were not seen on histologic
sections of the liver. Thus, it appears that TNF influences
the somatotroph axis through mechanisms not yet under-
stood. The observation that the marked decrease in serum
IGF-I levels in antiTNF antibody-treated mice was associated
with normal GH levels (and release in vitro) is consistent
with the notion that GH has no effect on fetal and early post-
natal growth (20), in which IGF-I and -II appear to play a
major role (21).
We have detected TNF mRNA in the thymus and spleen
on the 15th day of fetal life and at birth (Fig. 2 A), which
suggests the possibility of an involvement of TNF in lym-
phoid organ development. Indeed, the only conspicuous in-
ternal alterations shown by the antiTNF antibody-treated
mice at death were those of the lymphoid organs. The
thymuses of 2-d-old antiTNF antibody-treated mice were
very small and histologic examination showed a poorly de-
veloped medulla, in striking contrast with the thymic struc-
ture of control mice (Fig. 2 B) . On day 9, the average de-
crease in thymus weight of the antiTNF antibody-treated
mice was 56% (28 .7 ± 1.2 mg, n = 8 vs. 65 .6 ± 5 .6 mg,
n = 8; p <0.001), and on day 21 was 49% (104 ± 4.3 mg,
n = 5 vs. 204 ± 13.6 mg, n = 5; p = 0.01) . At this age,
however, no difference in histologic structure other than size
was seen; flow cytometry analysis of thymocyte suspensions
showed that the percentages of CD4+/CD8+,CD4-/CD8 - ,
and more mature CD4 - /CD8+,CD4+/CD8 - were com-
parable in both groups of mice (not shown). The spleens of
antiTNF antibody-treated mice were also smaller, with an
average decrease in weight of 39% on day 9 (30.0 ± 1.7 mg,
n = 8 vs. 48.6 ± 2.8, n = 8; p <0.001) and of 33% on
day 21 (80 ± 1.5 mg, n = 5 vs. 120 ± 6.5 mg, n = 5;
p = 0.002) . Histologic examination showed a poorly devel-
oped or absent white pulp, in contrast to control mice, a fea-
ture apparent on day 9 (Fig. 2 C). Flow cytometry analysis
of spleen cell suspensions revealed that the percentage of
sIgM+ cells for 4-wk-old antiTNF antibody-treated mice
was decreased as compared with controls (16.7 ± 2 .6%,
n = 4 vs. 34.7 ± 8.6%, n = 4; p = 0.01), a difference accen-
tuated when these values were calculated in totalcell number
(78% decrease of sIgM+ cells in antiTNF antibody-treated
mice; p = 0.03). Histological examination of the axillary
and inguinal lymph nodes from 3-wk-old mice revealed in
the antibody-treated mice a decreased cellularity and a lack
ofwell-formed cortical primary follicles (Fig. 2 D). The special-
ized postcapillary high endothelial venules from which lym-
phocytes migrate from blood into lymph nodes were more
difficult to find and had, when distinctly seen, an unusual
flat endothelial lining (Fig. 2 D), probably as a reflection of
decreased lymphocytic traffic and cytokine action on the
differentiation of these endothelial cells. A marked lym-
phopenia was observed in the blood of antiTNF antibody-
treated mice, both relative (46.1 ± 6.5 vs. 69 .6 ± 5.7% in
controls, n = 5 per group; p <0.05) and absolute (7.5
± 2.4 vs. 31.2 ± 5.1 x 103 lymphocytes/mm' in controls;
p <0.05). No conspicuous effect on hematopoiesis was seen
since: (a) RBC or platelet counts were similar in both groups
of mice; (b) using colony-forming cell assays in the presence
of IL-3 and erythropoietin, similar hematopoietic progenitor
numbers were found in the bone marrow or spleen cells of
antiTNF antibody-treated and control mice (not shown).
Since the thymus contains TNF mRNA, and also protein
(22), very early in its development, and since TNF acts in
vitro as a growth factor for thymocytes (23), in particular
in association with IL-2 (24), the effect of antiTNF antibody
is probably exerted locally. Presence of TNF within the thymus
may be required for optimal thymocyte proliferation, at least
during the period ofrapid thymus growth, and for the normal
colonization of peripheral lymphoid organs by T lympho-
cytes. However, the severe alterations of the spleen and pe-
ripheral lymph nodes encountered cannot be explained solely
on the basis of a depletion in T lymphocytes, as shown by
the decreased number of splenic B lymphocytes and the poor
development of lymph node primary follicles, which are B
cell structures preserved in athymic nude mice. It seems pos-
sible that a local production ofTNF is required in sites other
than the thymus, such as the spleen, to allow a normal pro-
cess of B cell expansion. TNF has been reported to enhance
B cell proliferation in vitro (25, 26). This may also take place
in indirect ways, through the stimulation of accessory cells
or the production of other cytokines involved in a network
necessary for the normal development ofthe lymphoid system,
but not required for that of hematopoiesis. SCID mice have
a profound atrophy of lymphoid organs, due to their failure
to produce T and B lymphocytes (27), but no obvious im-
pairment of early body growth. The effect of TNF on early
body growth is probably exerted through mechanisms dis-
tinct from those acting upon lymphoid tissue development,
and which remain to be elucidated.
Figure 2.
￿
(A) Detection of TNF transcripts by Northern Blot analysis in day 15 fetal thymus (lane a), spleen (lane b), and postnatal day 1 thymus
(lane c); 6 hg total RNA. (B) Marked decrease in size andmedullar depletion observed in the thymus of a 2-d-old pupfrom an antiTNFantibody-treated
mother (right, actual length of thymic lobe: 0.8 mm) as compared with control littermate (left, length of thymic lobe: 4mm) (x9) . (C) Lack of developed
splenic white pulp in a 9-d-old antiTNF antibody-treated mouse (right); the spleen is much smaller than that of a control, in which the white pulp
is distinctly seen (x6). (D) Comparable cortical regions of axillary lymph nodes show general lymphocyte depletion, lack of cortical follicles, and
postcapillary venules displaying flat endothelial cells (arrow) in 3-wk-old mice treated with antiTNF since birth (right), as compared with control (left,
normal postcapillary venule with high endothelial cells [arrow]). (x23).
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